**Periodic disclosure for the financial products referred to in Article 9, paragraphs 1 to 4a, of Regulation (EU) 2019/2088 and Article 5, first paragraph, of Regulation (EU) 2020/852**

**Product name:**

*Published on: 30 June 2026*

- MED PLATFORM II B
- MED PLATFORM II S.L.P.

**Legal entity identifier:**

- MED PLATFORM II B: 96950070Y2AQDMC5RT95
- MED PLATFORM II S.L.P.: 969500OH3NYQ1L684F15

**Sustainable investment** means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices.

The **EU Taxonomy** is a classification system laid down in Regulation (EU) 2020/852, establishing a list of **environmentally sustainable economic activities**. That Regulation does not include a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

# Sustainable investment objective

**Did this financial product have a sustainable investment objective?**

| ☒ **Yes** | ☐ **No** |
|---|---|
| ☐ It made **sustainable investments with an environmental objective:** ___% | ☐ It **promoted Environmental/Social (E/S) characteristics** and while it did not have as its objective a sustainable investment, it had a proportion of __% of sustainable investments |
| ☐ in economic activities that qualify as environmentally sustainable under the EU Taxonomy | ☐ with an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy |
| ☐ in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy | ☐ with an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy |
| | ☐ with a social objective |
| ☒ It made **sustainable investments with a social objective:** 100 % | ☐ It promoted E/S characteristics, but **did not make any sustainable investments** |

## To what extent was the sustainable investment objective of this financial product met?

Sustainable investment is embedded in the asset focus and the management approach of MED Platform II SLP (the "**Fund**") as an impact investment fund focused on contributing to one or more of the 17 United Nations Sustainable Development Goals (‘**UN SDGs’**), mainly SDG #3 “Good health and well-being” and its associated targets, and SDG #9 “Industry, innovation and infrastructure”, and its associated targets, through investments in healthcare companies developing innovative products, medical devices, or services with positive outcomes for patient or animal health conditions. ARCHIMED (the "**Management Company**") has developed a framework (see our Responsible Investment Policy) by which sustainable investments with a social objective can be identified though determining their contribution to ARCHIMED’s Health objectives: better efficiency, efficacy, safety, accessibility and affordability. These objectives seek to provide better healthcare outcomes at the doctor, patient, animal, and environmental level, through improvements to medical industries and services to hospitals and care providers. For our most recent funds (Article 8 (with sustainable investments) and 9), specific healthcare impact objectives and metrics have been relied upon to assess the performance of the sustainable investments. Table 1 provides a summary of 2025 performance.

| | Better efficiency | Better efficacy | Better safety | Better accessibility | Better affordability |
|---|---|---|---|---|---|
| **Natus Neuro** | **Sustainable Investment Objective**: Provide high-quality medical equipment, such as the BrainWatch Point-of-Care EEG and AutoScore solutions, providing neuro diagnostic and treatment products that offer efficiency gains to hospitals. | **Sustainable Investment Objective**: By investing in the continued education of medical professionals, provide learnings on new technologies advancements, Natus Neuro enhances the real-world efficacy of its solutions and generates positive, measurable impact on patient health outcomes. | **Sustainable Investment Objective**: Advance patient safety by reducing the risk of misdiagnosis and supporting more accurate clinical decision-making. This minimizes the potential for adverse outcomes across neurological care settings and ensuring patients receive timely and appropriate treatment. | **Sustainable Investment Objective**: By developing innovative EEG technologies, Natus Neuro seeks to expand access to critical brain monitoring in an easily deployable manner for both the emergency room and the ICU including those in underserved communities and regions. | |
| | **Sustainable Investment Contribution:** As demonstrated by Desai et al. (2024), point-of-care EEG provided by Natus products can significantly reduce Intensity Care Unit (ICU) length of stay (3.9 vs. 8.0 days) and enabled faster diagnosis (6.1 vs. 25.3 hours) compared to conventional EEG. | **Sustainable Investment Contribution:** >3,500 healthcare professionals were trained via Trade shows, Congresses, Local Master Classes, Virtual Training as well as Onsite training. | **Sustainable Investment Contribution:** Through the 90% accuracy of AutoScore, Natus Neuro's AI-powered EEG interpretation technology, which enables clinicians to reliably detect, classify, and act upon neurological events with greater confidence, reducing diagnostic error and enhancing the overall standard of patient safety in clinical practice. | **Sustainable Investment Contribution:** Donated >$250,000 worth of medical equipment in 2025 to underserved regions and communities.<br><br>Served >25 LMICs which accounts for more than 6% of global revenues, illustrating the group's ongoing commitment to make neurological solutions accessible to all. | |
| **Natus Sensory** | | | **Sustainable Investment Objective**: Improve patient safety across newborn, paediatric, and adult care settings by ensuring that clinicians are equipped with the knowledge and technical proficiency to accurately deploy its hearing screening, audiology diagnostics, balance assessment, and vision care solutions. | **Sustainable Investment Objective**: Through making the entire portfolio of >100 products available in all major markets and LMICs, seek to expand access to diagnostic and treatment of sensory solutions for all healthcare professionals and in turn provide better care for patients globally. | |
| | | | **Sustainable Investment Contribution:** Trained >400 clients on the safe and effective use of Natus Sensory's product portfolio.<br><br>The industry-leading precision of the ALGO | **Sustainable Investment Contribution:** >100 products distributed globally<br><br>Serving >15 LMICs which generates approximately 5% of global revenues | |

| | | | | | |
|---|---|---|---|---|---|
| | | | Newborn Hearing Screening device achieves clinically proven sensitivity exceeding 99% and specificity exceeding 96% which has been validated across more than 14 peer-reviewed publications. | demonstrating Natus Sensory's commitment to expanding access to sensory solutions globally. | |
| **Jeisys Medical** | | **Sustainable Investment Objective**: Provide energy-based devices effectively addressing skin diseases with long-lasting effects, reducing the need for multiple sessions. | **Sustainable Investment Objective**: Through its medical-grade devices, ensure patient safety by reducing the prevalence of side effects vs. comparable alternatives in the market. | **Sustainable Investment Objective**: Provide devices designed to effectively treat skin diseases across all Fitzpatrick skin types, ensuring that a broader range of patients can benefit from these treatments. | |
| | | **Sustainable Investment Contribution:** >50% share of revenue contributing to addressing skin diseases. | **Sustainable Investment Contribution:** >40 countries where the medical devices are approved. | **Sustainable Investment Contribution:** 100% Fitzpatrick skin types covered by Radio Frequency and High Intensity Focused Ultrasound devices. | |
| **Instem** | **Sustainable Investment Objective**: Through SaaS platforms that streamline R&D, study management, regulatory submissions and clinical trial analytics, enable healthcare clients to capture, analyze and submit compliant data more efficiently, accelerating drug and therapy development. | | **Sustainable Investment Objective**: Through in silico toxicology, safety analytics and standardized data formats that help predict adverse effects earlier, strengthen safety risk assessments and support robust, regulatory compliant decision-making across the product lifecycle. | | |
| | **Sustainable Investment Contribution:** 24 digital health solutions offered. | | **Sustainable Investment Contribution:** 236k+ chemical structures with toxicity profiles mapped. | | |
| **Irrimax** | | **Sustainable Investment Objective**: High-efficacy products such as Irrisept eliminate most bacteria from wounds and effectively mitigate hospital-acquired conditions, helping hospitals improve patient outcomes and reduce the risk of surgical site infections (SSIs). | **Sustainable Investment Objective**: Protect and enhance patient safety during surgery, immunotherapy, immunosuppression, and chemotherapy due to the higher risk of antimicrobial resistance (AMR) which can often limit the effectiveness of alternative solutions and treatments. | | **Sustainable Investment Objective**: Irrisept acts as a safer replacement for antibiotics used to treat SSIs without increasing the risk of AMR. |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | **Sustainable Investment Contribution:** A clinical study conducted with UHS of Delaware demonstrates that integrating Irrisept into routine colon surgery can reduce the post-operative SSI rate from 5.88% to 2.09%, representing a 64% improvement in efficacy in comparasion to conventional wound irrigation solutions. | **Sustainable Investment Contribution:** A 2022 study showed Irrisept's 30-day readmission rate of just 0.5% compared to 3.7% for conventional betadine irrigation representing a 84% reduction in readmission likelihood. Complaint rate of <0.003% across >1.6 million units sold and a 100% client recommendation rate. | | | **Sustainable Investment Contribution:** Driesman et al. (2020), Irrisept achieves a 0.78% periprosthetic joint infection rate compared to 1.14% for betadine across a study of 2,386 patients, generating estimated cost savings from of $437,500 from readmissions in the study and up to $3,150,000 at 10,000 surgeries. |
| **PlasmidFactory** | **Sustainable Investment Objective**: Support healthcare and academic clients in advancing their research and clinical programmes on areas like cell and gene therapy, CAR-T cell development, and genetic vaccination, through manufacturing high-purity plasmid and minicircle DNA products optimized for efficient transfection and GMP-compliant. | | | **Sustainable Investment Objective**: Accelerate collective progress in the field of DNA production through in-house product innovation and R&D collaborations with research institutions focused on testing novel methodologies and sharing scientific knowledge in significant publications. | |
| | 99.2% client satisfaction rate and 19 days average turnaround time for Scientific Quality Grade projects. | | | >3,500 different plasmids & minicircles manufactured. | |
| **ZimVie** | | **Sustainable Investment Objective:** By offering cutting-edge implant systems, evidence-based biomaterials, and digitally guided workflows, enhance procedural accuracy, reducing complications, and empowering healthcare professionals in delivering more predictable outcomes. | | **Sustainable Investment Objective**: Improve global access to high-quality implant dentistry by lowering the barriers to adoption of advanced digital surgical workflows, expanding the reach of its solutions to general dental practitioners and healthcare providers across diverse geographies. | |
| | | **Sustainable Investment Contribution:** 97.4% long-term implant survival rate across ZimVie's TSV and TSX implant systems, underpinned by prospective clinical data across over 1,500 implants with follow- | | **Sustainable Investment Contribution:** >400 general dentists across 42 countries have adopted ZimVie's RealGUIDE digital workflow platform. The RealGuide Solution reduces treatment planning through automation, while facilitating predictable | |

| | | | | | |
|---|---|---|---|---|---|
| | | up periods ranging from 3 to 120 months. | | implant placement and creating a safer, more easily repeatable surgical process. | |
| **ARK Diagnostics** | | | **Sustainable Investment Objective**: Achieve rigorous quality certifications (ISO 13485, MDSAP, IVDR) and a clean FDA audit record, ensuring the reliability and safety of the products. | **Sustainable Investment Objective**: through a global distribution network, making therapeutic drug monitoring accessible worldwide, including underserved markets. | |
| | | | **Sustainable Investment Contribution:** 7 quality management certifications obtained by the Company, including ISO 13485, MDSAP, and IVDR, alongside a clean FDA audit record, ensuring the reliability and safety of its products across all markets. | **Sustainable Investment Contribution:** >60 countries where products are available, including 13 LMICs, reflecting both a broad global footprint and a meaningful contribution to expanding access to healthcare in underserved markets. | |
| **Ceva** | | **Sustainable Investment Objective**: Through sustained R&D investment in innovative, more targeted vaccines and treatments such as Forceris, raise therapeutic success rates, reduce repeated treatments, and support the shift toward more preventive, effective, and sustainable veterinary practices. | **Sustainable Investment Objective**: Through the GRAM program, support veterinarians and livestock farmers in adopting preventive approaches, notably vaccination, over curative antibiotic treatments, reducing antimicrobial use and bacterial selection pressure to help mitigate AMR. | **Sustainable Investment Objective**: Training of paravets in LMICs, strengthening local veterinary capacity, expanding access to animal care in underserved rural areas, and supporting farmers' resilience and food security. | |
| | | **Sustainable Investment Contribution:** 39% market penetration rate of Forceris, reflecting the broad adoption of a high-efficacy solution. | **Sustainable Investment Contribution:** >5,500 participants engaged in the Company's GRAM programme, supporting veterinarians and livestock farmers in shifting from curative antibiotic use to preventive approaches. | **Sustainable Investment Contribution:** 225 paravets trained by the Company in LMICs strengthening local veterinary capacity and expanding access to animal care in underserved rural areas where professional veterinary services remain scarce. | |

*Table 1: MED Platform II 2025 sustainable investments' performance*

Please refer to ARCHIMED's Sustainability & Impact Report for detailed 2025 information on MED Platform II companies' sustainability performance.

**Sustainability indicators** measure how the environmental or social characteristics promoted by the financial product are attained.

**Principal adverse impacts** are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anti-

***How did the sustainability indicators perform?***

All investee companies of MED Platform II have completed their 2025 ESG reporting. For details on 2025 vs. 2024 performance, please refer to Appendix I.

***…and compared to previous periods?***

As above.

***How did the sustainable investments not cause significant harm to any sustainable investment objective?***

MED Platform II's investment strategy is focused on the contribution to SDG 3 (and where applicable, SDG 9) and associated targets. This strategy dictates that the investments of the Fund will undergo a pre-investment screening and ESG due diligence to ensure that not only does the Fund contribute to social objectives, but that it will do no significant harm' (**DNSH**) to other sustainable investment objectives mainly through the collection and analysis of Principal Adverse Impacts indicators.

Please refer to Appendix I for more information.

*How were the indicators for adverse impacts on sustainability factors taken into account?*

During the investment cycle, the ESG Due diligence assesses indicators that would indicate presence or absence of a principal adverse impact (PAI). These indicators include, in compliance with the SFDR and Delegated regulation, the following principal adverse impacts:

- Environmental damage, GHG emissions; carbon footprint; GHG intensity of Investee companies; exposure to companies active in the fossil fuel sector; share of non-renewable energy consumption and production; energy consumption intensity per high impact climate sector; activities negatively affecting biodiversity-sensitive areas; emissions to water; hazardous waste ratio.
- Social and employee matters, violation of UN Global Compact principles and OECD Guidelines for Multinational Enterprises; lack of processes and compliance mechanisms to monitor compliance with UN Global Compact principles and OECD Guidelines for Multinational Enterprises; unadjusted gender pay gap; board gender diversity; exposure to controversial weapons.
- In addition to the mandatory PAIs, two additional PAIs are taken into account: 1) "Investments in companies without carbon emission reduction initiatives aimed at aligning with the Paris Agreement", which was chosen due to ARCHIMED's focus on climate as a central pillar within our responsible investment strategy; and 2) "Share of investments in investee companies without workplace accident prevention policy" which was selected due to the particular importance of health in safety in the workplace of healthcare

businesses, which may be exposed to particular chemicals, machinery or other occupational hazards beyond that of a typical office environment.

Furthermore, our responsible investment strategy is embedded into all steps of our investment lifecycle and is focused on supporting the progress of our investee companies' sustainability performance. For this purpose, we work collaboratively with our investee companies in developing tailored Sustainability and Impact Roadmaps that help set clear objectives, assign internal responsibilities, and monitor progress over time. These Roadmaps are validated at board level and executed by the company's management team as a concrete action plan to advance ESG and sustainability performance, as well as ultimately their PAI results, while also simultaneously contribute to the achievement of the social sustainable objective of the fund. If risks or incidents arise, ARCHIMED identifies any potential corrective action plans and implements active measures to mitigate the identified risks.

To further align business interests with sustainability and impact objectives, ARCHIMED has mandated a percentage of the CEO's variable remuneration is linked to the achievement of specific objectives of their Sustainability Roadmap, which may improve their PAIs over the holding period.

The ARCHIMED team supports the investee companies in their sustainability journey through regular engagement with company management and monitors company progress against this Roadmap through formal follow-up reviews which are performed on an annual basis. Results on the PAIs for this Fund are available in Appendix I.

*Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:*

Yes, the Management Company ensures investee companies are aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights.

This information is gathered as part of our annual ESG reporting process and is carried out across all portfolios. ARCHIMED policies require MED Platform II to perform appropriate due diligences on its own activities, investments, and business relationships to enable appropriate action to be taken in the event of any findings of non-compliance. ARCHIMED ensures human rights, equality and anti-bribery and corruption policies are in place and that there are not any instances of child, forced, or compulsory labour.

*The EU Taxonomy sets out a "do not significant harm" principle by which Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.*

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the Union criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the Union criteria for environmentally sustainable economic activities.

*Any other sustainable investments must also not significantly harm any environmental or social objectives.*

**How did this financial product consider principal adverse impacts on sustainability factors?**

PAIs are considered throughout the entire investment cycle, from the initial negative and positive screening phases through due diligence.

During the due diligence phase, an assessment is conducted to verify the company's readiness to report on PAI metrics. This assessment helps identify existing gaps which can then be addressed in the early stages of onboarding and/or during ARCHIMED annual ESG reporting campaign and hold period.

Our ESG reporting process monitors this by asking investee companies for PAI-related data on an annual basis. Any material impacts are discussed during the annual follow-up reviews, which takes place at the end of the campaign. Please refer to Appendix I for more information.

## What were the top investments of this financial product?

The list includes the investments constituting **the greatest proportion of investments** of the financial product during the reference period which is:

**<u>01/01/25 – 31/12/25</u>**

| Largest investments | Sector | % Assets[1] | Country |
|---|---|---|---|
| Jeisys Medical | Consumer Health | 18.4 | South Korea |
| Natus Neuro | MedTech | 18.0 | USA |
| ZimVie | MedTech | 15.8 | USA |
| Instem | Healthcare IT | 14.4 | UK |
| Ceva Sante Animale SA | Animal and Environmental Health | 9.2 | France |
| Irrimax | MedTech | 7.8 | USA |
| ARK Diagnostics | Diagnostics | 6.2 | USA |
| Plasmid Factory | Life Sciences Tools | 5.2 | Germany |
| Natus Sensory | MedTech | 5.0 | USA |

## What was the proportion of sustainability-related investments?

The proportion of sustainability-related investments in MED Platform II is 100% as the Fund is classified as Article 9 and therefore contributes to sustainable investment objectives.

**Asset allocation** describes the share of investments in specific assets.

### *What was the asset allocation?*




As an Article 9 classified fund, MED Platform II's asset allocation is 100% sustainable investment with social objectives.

[1] The percentage of assets is calculated based on invested amounts and excluding cash.

To comply with the EU Taxonomy, the criteria for **fossil gas** include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For **nuclear energy**, the criteria include comprehensive safety and waste management rules.

**Enabling activities** directly enable other activities to make a substantial contribution to an environmental objective.

**Transitional activities are** activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.

Taxonomy-aligned activities are expressed as a share of:
- **turnover** reflecting the share of revenue from green activities of investee companies
- **capital expenditure** (CapEx) showing the green investments made by investee companies, e.g. for a transition to a green economy.
- **operational expenditure** (OpEx) reflecting green operational activities of investee companies.

***In which economic sectors were the investments made?***

All investments made through MED Platform II lifetime were made in healthcare industries across seven different sectors (percentage calculation based on invested amounts and excluding cash):
- Biopharma Products
- Consumer Health: 1 investment (c. 18%)
- Healthcare IT: 1 investment (c. 14%)
- Diagnostics: 1 investment (c. 6%)
- Life Science Tools: 1 investment (c. 5%)
- MedTech: 4 investments (c. 47%)
- Animal & Environmental Health: 1 investment (c. 9%)

## To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

MED Platform II carries out sustainable investments with social objectives as part of our Funds' strategy, which is therefore not based on EU Taxonomy alignment.

**Did the financial product invest in fossil gas and/or nuclear energy related activities that comply with EU Taxonomy[2]?**

☐ Yes :

☐ In fossil gas ☐ In nuclear energy

☒ No

[2] Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objective – see explanatory note in the left hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

**Reference benchmarks** are indexes to measure whether the financial product attains the environmental or social characteristics that they promote.

***The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investment of the financial product other than sovereign bonds.***







This graph represents 100% of the total investment.

****For the purpose of these graphs, "sovereign bonds" consist of all sovereign exposure.***

- ***What was the share of investments made in transitional and enabling activities?***

Not applicable. The Fund does not invest or plan to invest in transitional nor enabling activities in the sense of the EU Taxonomy.

- ***How did the percentage of investments that were aligned with the EU Taxonomy compared with previous reference periods?***

Not applicable. MED Platform II's investments do not follow an environmentally sustainable investment objective in the sense of the EU Taxonomy. Instead, they focus on the attainment of a social sustainable investment objective.

## What was the share of sustainable investments with an environmental objective not aligned with the EU Taxonomy ?

MED Platform II's investments do not pursue an environmental objective as laid out in the EU Taxonomy. Hence, 0% of the Fund's investments are aligned with the EU Taxonomy.

are sustainable investments with an environmental objective that **do not take into account the criteria** for environmentally sustainable economic activities under Regulation (EU) 2020/852.

## What was the share of socially sustainable investments ?

100% of MED Platform II's investments are sustainable investments with a social objective. For more details, please refer to the above answer to the question; "To what extent was the sustainable investment objective of this financial product met?", as well as our Sustainability and Impact Report.

## What investments were included under "not sustainable", what was their purpose and were there any minimum environmental or social safeguards ?

None of MED Platform II's investment fall into this category.

## What actions have been taken to attain the sustainable investment objective during the reference period?

During the reference period, ESG and Impact data were collected for all investee companies, comprising metrics based on SASB and other applicable standards. At the end of the reference period, follow-up reviews were conducted including overall progress, gap analysis and establishment of priorities for 2026.

Specific actions implemented at investee companies' level are specified in our Sustainability and Impact Report, and regularly to our investors in quarterly reports of the Fund.

## How did this financial product perform compared to the reference sustainable benchmark?

Not applicable. The Fund does not use a benchmark.

- ***How does the reference benchmark differ from a broad market index?***

  Not applicable.

- ***How did this financial product perform with regard to the sustainability indicators to determine the alignment of the reference benchmark with the sustainable investment objective?***

  Not applicable.

- ***How did this financial product perform compared with the reference benchmark?***

  Not applicable.

- ***How did this financial product perform compared with the broad market index?***

  Not applicable.

## APPENDIX I: ARCHIMED MED Platform II Principal Adverse Impact Indicators 2025/2024

| Adverse sustainability indicator | | Metric | Unit | 2025 | 2024 | Explanation[12] | Actions Taken |
|---|---|---|---|---|---|---|---|
| **CLIMATE AND OTHER ENVIRONMENT-RELATED INDICATORS** | | | | | | | |
| GHG (Greenhouse Gas) Emissions | 1. GHG emissions (GP share) | Scope 1 GHG emissions and | tonnes | 2,642 | 6,380 | During the reference period, ARCHIMED applied the same methodology for calculating its financed emissions, thereby keeping consistency and comparability across years. The data reported in the period represents an improvement compared to the previous period due to a higher proportion of activity data reported and more accurate sectoral estimates for companies that are yet to complete a carbon footprint assessment.<br><br>When comprehensive carbon emissions data are not available for the reference period, prior year emissions data (2024) are scaled using a revenue-based extrapolation. When investee companies cannot provide carbon emissions data, ARCHIMED adopts a sectoral estimate approach using the *ADEME Base Empreinte* database for NACE-code-based estimations. Each NACE code is linked to an emission factor (in $tCO_2e$ per M€ of revenue). The footprint is then calculated by multiplying the company's revenue by this factor. | During 2025, four companies in MED Platform II have progressed to deliver their first carbon footprint assessments, resulting in the fund using actual physical and operational portfolio level data rather than sectoral estimates, supporting a reduction in reported emissions between 2024 and 2025. ARCHIMED's S&I Team is currently working with the remaining investee companies to ensure a carbon footprint assessment is conducted over the course of 2026 and carbon reduction initiatives are defined.<br><br>ARCHIMED continues to adopt the PMDR (Private Markets Decarbonization Roadmap) framework across all funds, which provides a standardized framework for private equity firms for the structured and transparent reporting of decarbonization strategies and goals across the portfolio. As of FY2025, more than 70% of the MED Platform II investee companies are capturing data and/or preparing to decarbonize with action plans in place to reduce their emissions. |
| | | Scope 2 GHG emissions | tonnes | 2,012 | 4,055 | | |
| | | Scope 3 GHG emissions | tonnes | 80,868 | 88,818 | | |
| | | Total GHG emissions | tonnes | 85,521 | 99,254 | | |
| | 2. Carbon footprint | Carbon footprint | tonnes/ €M | 36 | 71 | | |
| | 3. GHG intensity of investee companies | GHG intensity of investee companies | tonnes/ €M | 133 | 294 | | |

[12] The Fund has strictly followed the definitions of Annex I of the Final Report on draft Regulatory Technical Standards, dated 4 December 2023, for compiling the various PAI indicators.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | 4. Exposure to companies active in the fossil fuel sector | Share of investments in companies active in the fossil fuel sector | % | Nil | Nil | ARCHIMED invests exclusively in companies across the healthcare industries and thus has no exposure to the fossil fuel sector. | Not applicable |
| | 5. Share of non-renewable energy consumption and production | Share of non-renewable energy consumption and non-renewable energy production of investee companies from non-renewable energy sources compared to renewable energy sources, expressed as a percentage | % | 83 | 65 | The addition of three new companies to the fund in 2025 has resulted in an increase in the year-on-year difference for non-renewable energy consumption and production. Nevertheless, energy efficiency initiatives continue to be identified across investee to reduce reliance on non-renewable energy in the coming years.<br><br>Additionally, ARCHIMED takes a conservative approach by allocating the totality of energy consumption to non-renewable energy when the investee company is unable to provide the categorization. | During the reference period, ARCHIMED's MED Platform II investee companies implemented and progressed a range of initiatives aimed at reducing their environmental footprint across energy efficiency, waste management and circular economy principles.<br><br>Several investee companies have embedded energy efficiency considerations into operational practices, including the ongoing monitoring of energy usage, installation of solar panels and energy-efficient lighting and equipment.<br><br>Another notable development during the reference period is one investee company's ongoing migration from a smaller data centre provider to Microsoft Azure, a transition expected to deliver significant energy efficiency gains.<br><br>These initiatives reflect the growing environmental awareness across the portfolio and will continue to be monitored and supported by the ARCHIMED S&I team as part of the fund's Sustainability Essentials. |
| | 6. Energy consumption intensity per high impact climate sector | Energy consumption in GWh per million EUR of revenue of investee companies, for climate sector: Manufacturing | GWh/ €M | 0.02 | 0.01 | | |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Biodiversity | 7. Activities negatively affecting biodiversity-sensitive areas | Share of investments in investee companies with sites/operations located in or near to biodiversity-sensitive areas where activities of those investee companies negatively affect those areas | % | Nil | Nil | Investee companies in the fund do not have any sites/operations located in or near biodiversity-sensitive areas where they could negatively affect those areas. | A preliminary fund-level biodiversity risk screening of investee company sites was conducted in 2025 by the ARCHIMED S&I team to identify potential biodiversity risks relating to investments. Based on the initial geolocation and sectoral based results, dependency on ecosystem services has been identified as the most common and priority risk exposure across investee companies.<br><br>This reflects the reliance of the healthcare sector on water availability, local ecosystems and functioning supply chains. This initial assessment marks an important first step for ARCHIMED in improving its understanding of its portfolio nature-related risk exposure. |
| Water | 8. Emissions to water | Tonnes of emissions to water generated by investee companies per million EUR invested, expressed as a weighted average | tonnes/ €M | Nil | Nil | Investee companies in the fund do not generate emissions to water. | During the reference period, one investee company began to deploy a regrind manufacturing process for its new product line to recycle plastic scrap in bottle formation to ensure operational efficiency whilst also meeting broader emission reduction and waste management targets.<br><br>ARCHIMED's S&I team will continue to actively support investee companies, particularly recently invested ones, to establish robust environmental data tracking and reporting systems, ensuring that energy, waste, water and other key KPIs are accurately identified, categorized and measured in line with applicable regulatory definitions. |
| Waste | 9. Hazardous waste ratio | Tonnes of hazardous waste generated by investee companies per million EUR invested, expressed as a weighted average | tonnes/ €M | 0.01 | 0.01 | The majority of ARCHIMED's investee companies are not directly involved in heavy manufacturing resulting in low amount of hazardous waste being reported. It is worth noting that as investee companies evolve and mature in ESG data collection, the processes of tracking and reporting waste data will improve. This means that reported figures for some companies may not yet capture the full picture, and values are expected to become more accurate in future reporting periods. | |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| ARCHIMED Additional Environmental Indicator | 4. Investments in companies without carbon emission reduction initiatives | Share of investments in investee companies without carbon emission reduction initiatives aimed at aligning with the Paris Agreement | % | 93 | 100 | The relatively low share of investee companies with formal carbon emission reduction targets in place (1 out of 9 companies) reflects the nascent stage of the decarbonization journey across the portfolio, rather than a lack of commitment to climate action.<br><br>The majority of ARCHIMED's investee companies are small-to-mid-sized enterprises operating in specialized healthcare sectors where structured climate targets can be less developed. Nevertheless, encouragingly meaningful progress has been made during 2025: four investee companies have now completed their first carbon footprint assessment and have identified initial and feasible carbon reduction actions across scopes 1, 2 and 3 emissions which is a critical foundational step before any science-based or Paris-aligned targets can be responsibly set. | Investee companies operate predominantly in the healthcare sectors, where structured, Paris-aligned carbon reduction frameworks and net-zero commitments are less established. Nevertheless, investee companies have made significant efforts to reduce their carbon footprint and improve energy efficiency, demonstrating meaningful progress toward emissions reduction even in the absence of formally documented Paris-aligned strategies. Actions taken at the portfolio level include the procurement of electricity from renewable energy providers, eco design and packaging reduction measures and the installation of energy consumption monitoring systems to establish baseline data and track efficiency improvements over time. ARCHIMED's climate approach is designed to support companies in: (1) accurately measuring their emissions, and (2) setting pragmatic, achievable targets aligned with long-term value creation. This phased methodology prioritizes the implementation of practical actions and the establishment of reliable data foundations before committing to formalized targets, ensuring that climate strategies are both credible and value driven. |

| Adverse sustainability indicator | | Metric | Unit | 2025 | 2024 | Explanation[13] | Actions Taken |
|---|---|---|---|---|---|---|---|
| **SOCIAL AND EMPLOYEE, RESPECT FOR HUMAN RIGHTS, ANTI-CORRUPTION AND ANTI-BRIBERY MATTERS** | | | | | | | |
| Social and Employee Matters | 10. Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises | Share of investments in investee companies that have been involved in violations of the UNGC principles or OECD Guidelines for Multinational Enterprises | % | Nil | Nil | No violations took place across the fund in 2025. | As part of ARCHIMED's Sustainability Essentials framework, investee companies are encouraged to develop and maintain policies on the following non-exhaustive, social and governance topics:<br>(a) Code of Conduct, Anti-Bribery and Corruption, Grievance and Whistleblowing Mechanism<br>(b) Employee Wellbeing & Engagement Approach<br>(c) Responsible Supply Chain<br>(d) Health and Safety<br>(e) Cybersecurity and Data Privacy and Protection<br>Potential ESG incidents and controversies are also assessed through multiple channels such as the annual ESG Reporting Campaign and through ongoing engagement with deal team members. ESG topics are also discussed at board level at least twice per year, with ARCHIMED holding multiple board seats across its portfolio.<br>In addition to the Sustainability Essentials, ARCHIMED Value Creation Teams (VCTs) support investee companies in strengthening governance frameworks, ensuring high standards of corporate governance, accountability, and transparency. |
| | 11. Lack of processes and compliance mechanisms to monitor compliance with UN Global Compact principles and OECD Guidelines for Multinational Enterprises | Share of investments in investee companies without policies to monitor compliance with the UNGC principles or OECD Guidelines for Multinational Enterprises or grievance /complaints handling mechanisms to address violations of the UNGC principles or OECD Guidelines for Multinational Enterprises | % | 41 | 19 | The addition of three new companies to the fund in 2025 has resulted in an increase in the year-on-year difference. ARCHIMED is committed to working with new investee companies to develop a sustainability roadmap which covers key social and governance matters such as monitoring compliance with UNGC principles and OECD guidelines. | |

[13] The Fund has strictly followed the definitions of Annex I of the Final Report on draft Regulatory Technical Standards, dated 4 December 2023, for compiling the various PAI indicators.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Social and Employee Matters | 12. Unadjusted gender pay gap | Average unadjusted gender pay gap of investee companies | % | 21 | 17 | The year-on-year increase in the unadjusted gender pay gap is attributable to the addition of three new companies to the fund during 2025. It is important to note that these companies are still at an early stage in their ESG maturity journey and aim to implement improvement measures over the years to come.<br><br>The unadjusted gender pay gap does not account for differences in role, seniority, or function, and as such does not necessarily reflect unequal pay for equivalent work. | ARCHMED works closely with all investee companies to ensure they are fostering a diverse, equitable, and inclusive working environments. Through ARCHIMED's Sustainability Essentials and ongoing engagement, investee companies are required to implement employee engagement programs, surveys and support career development for all employees. Several companies have formalized their commitments through employee engagement and training programs which helps to foster connection, understanding and allow questions for deeper understanding and appreciation of difference cultures and backgrounds. One investee company established an Employee Resource Group (ERG) which is designed to provide a safe and open environment for all global employees to connect and share ideas. In addition to this, the company has launched its Women Inspired Network ERG, dedicated to supporting and empowering women across the global organization and communities it serves. |
| | 13. Board gender diversity | Average ratio of female to male board members in investee companies | % | 7 | 8 | | |
| | 14. Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons) | Share of investments in investee companies involved in the manufacture or selling of controversial weapons | % | Nil | Nil | ARCHIMED invests exclusively in companies across the healthcare industries and thus has no exposure to controversial weapons. | Not applicable. |
| ARCHIMED Additional Social Indicator | 1. Investments in companies without workplace accident prevention policies | Share of investments in investee companies without a workplace accident prevention policy | % | 14 | 31 | The majority companies in the fund have health and safety policies that include accident prevention and safeguarding measures. The remaining company operates in an office building. ARCHIMED continues to monitor all investee companies and ongoing engagement to ensure that necessary policies and procedures to ensure that risks are identified and safeguarding processes are embedded. | Investee companies perform regular formal or informal health & safety risk assessments in line with national and sectoral health and safety regulations and guidelines The risk assessment approach can vary depending on business activity and regional regulation. |